HER2-positive breast cancer was considered an aggressive subtype with a worse prognosis, but the development of anti-HER2 agents changed this paradigm. In the last years, the treatment of early HER2 breast cancer patients faced several improvements. Different anti-HER2 targeted drugs, like trastuzumab, pertuzumab, lapatinib, and TDM-1 used in advanced disease started to be included in multimodal curative strategies. Further, the presence of complete pathological response to neoadjuvant treatments started to be used as a surrogate outcome and led to the development of post-neoadjuvant strategies. Here, we summarise the neoadjuvant and post-neoadjuvant treatments of HER2-positive breast cancer according to the best evidence, reviewing the pharmacological aspects of HER2 targeted agents.
(BELG J MED ONCOL 2021;15(1):4-10)